Tango Therapeutics, Inc.
TNGX
Classificação em ações
#4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Preço da ação
$27.18
Última sincronização: 2026-07-31
Valor de mercado
$3.38B
Variação (1 dia)
-1.41%
Variação (1 ano)
202.34%
País
US
Negociar Tango Therapeutics, Inc. (TNGX)
Categoria
Healthcare
Receita da Tango Therapeutics, Inc. (TNGX)
Receita em Jun 2026 TTM: $53.81M
De acordo com os últimos relatórios financeiros da Tango Therapeutics, Inc., a receita atual da empresa (TTM) é $53.81M. Em 2023, a empresa obteve uma receita de $36.53M um aumento em relação a a receita do ano 2022, que foi de $24.86M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Tango Therapeutics, Inc. de 2019 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $53.81M | 27.91% |
| 2024 | $42.07M | 15.17% |
| 2023 | $36.53M | 46.93% |
| 2022 | $24.86M | -32.89% |
| 2021 | $37.04M | 383.83% |
| 2020 | $7.66M | -68.94% |
| 2019 | $24.65M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 23,360.44% |
US
|
|
| $2.23B | 4,040.42% |
US
|
|
| $15.74B | 29,158.57% |
AU
|
|
| $6.02B | 11,089.70% |
NL
|
|
| - | - |
CH
|
